Novel insights into paclitaxel’s role on tumor-associated macrophages in enhancing PD-1 blockade in breast cancer treatmentYoonjeong Choi, Seong A Kim, Hanul Jung, Eunhae Kim, Yoon Kyoung Kim, Seohyun Kim, Jaehyun Kim, Yeji Lee, Min Kyoung Jo, Jiwan Woo, Yakdol Cho, Dongjoo Lee, Hongyoon Choi, Cherlhyun Jeong, Gi-Hoon NamSee the full list of authors
15 July 2024
Assessing the implications of sentinel lymph node removal in cervical cancer: an immunogenetic perspective – a SENTICOL ancillary studyGaurav Thareja, Anna Salvioni, Françoise Lauzeral-Vizcaino, Najeeb Halabi, Eliane Mery-Lamarche, Noemie Thebault, Clara-Maria Scarlata, Marie Michelas, Anne-Sophie Navarro, Gwenaël Ferron, Fabrice Lecuru, Patrice Mathevet, Jonathan Khalifa, Maha Ayyoub, Arash RafiiSee the full list of authors
15 July 2024
Cantharidin overcomes IL-2Rα signaling-mediated vorinostat resistance in cutaneous T-cell lymphoma through reactive oxygen speciesMan Zhu, Wenjun Tang, Xiaoyu Tang, Zeren Zhu, Yina Jiang, Ammar Sarwar, Hongmei Zhang, Dake Chu, Zixi Zhang, Yanmin Zhang
14 July 2024
Plasma metabolomics of immune-related adverse events for patients with lung cancer treated with PD-1/PD-L1 inhibitorsJuan Chen, Jia-Si Liu, Jun-Yan Liu, Lei She, Ting Zou, Fan Yang, Xiang-Ping Li, Zhan Wang, Zhaoqian Liu
11 July 2024
Harnessing lipid metabolism modulation for improved immunotherapy outcomes in lung adenocarcinomaYang Chen, Yu Zhou, Ran Ren, Yu Chen, Juan Lei, Yongsheng Li
8 July 2024
Infliximab in steroid-refractory immune-related hepatitis does not demonstrate hepatotoxicity and may shorten time on steroidsElias Burri, Joanna Mangana, Phil F Cheng, Alia Schneider, Achim Weber, Reinhard Dummer, Egle Ramelyte
5 July 2024
Impact of isotype on the mechanism of action of agonist anti-OX40 antibodies in cancer: implications for therapeutic combinationsJane E Willoughby, Lang Dou, Sabyasachi Bhattacharya, Heather Jackson, Laura Seestaller-Wehr, David Kilian, Laura Bover, Kui S Voo, Kerry L Cox, Tom Murray, Mel John, Hong Shi, Paul Bojczuk, Junping Jing, Heather NiedererSee the full list of authors
4 July 2024
Unique immune characteristics and differential anti-PD-1-mediated reinvigoration potential of CD8 TILs based on BRCA1/2 mutation status in epithelial ovarian cancersJunsik Park, Jung Chul Kim, Yong Jae Lee, Sunghoon Kim, Sang Wun Kim, Eui-Cheol Shin, Jung Yun Lee, Su-Hyung Park
4 July 2024
Second-generation checkpoint inhibitors and Treg depletion synergize with a mouse cancer vaccine in accordance with tumor microenvironment characterizationWilliam Becker, Purevdorj B Olkhanud, Noriko Seishima, Paloma A Moreno, Katherine C Goldfarbmuren, Hoyoung M Maeng, Jay A Berzofsky
1 July 2024
Fc–Fc interactions and immune inhibitory effects of IgG4: implications for anti-PD-1 immunotherapiesWeifeng Zhang, Xueling Chen, Xingxing Chen, Jirui Li, Hui Wang, Xiaomiao Yan, Han Zha, Xiaonan Ma, Chanyuan Zhao, Meng Su, Liangli Hong, Penghao Li, Yanyu Ling, Wenhui Zhao, Yu XiaSee the full list of authors
25 June 2024